TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma

Bychkov, Andrey; Sampatanukul, Pichet; Shuangshoti, Shanop; Keelawat, Somboon

doi:10.1016/j.pathol.2016.04.002

Cited by 36 publications

(49 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies, except one, demonstrated that TROP-2 was negative in neoplastic and non-neoplastic benign thyroid tissues [15,16,17]. Addati et al reported TROP-2 positivity in 4 non-neoplastic thyroid tissues and 2 cases of follicular adenoma [14].…”

Section: Discussionmentioning

confidence: 99%

“…TROP-2, which is expressed on normal levels in various normal tissues especially placenta, is related to tumor growth, tumor progression and the invasiveness of tumor cells [13]. Recently, there have been studies reporting that TROP-2 may be used in the differential diagnosis of follicular epithelial cell derived thyroid lesions [14,15,16,17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Mürtezaoğlu¹,

Güçer²

2017

pjp

View full text Add to dashboard Cite

In this study, we compared the diagnostic value of TROP-2 expression in distinguishing between benign and malignant thyroid lesions to those of HBME-1, CK19 and galectin-3. We selected 102 cases from our archive including 20 normal thyroid tissues, 23 follicular nodular diseases, 17 follicular adenomas, 20 follicular variant papillary carcinomas and 22 classical variant papillary carcinomas. Tissue microarrays constructed from these cases were immunohistochemically analyzed with HBME-1, CK19, galectin-3 and TROP-2. Respectively 73.8%, 83.3%, 69% and 50% of all papillary carcinomas were positive with HBME-1, CK19, galectin-3 and TROP-2. CK19 was positive respectively by 100%, 43.5% and 35.3% in cases of normal thyroid, follicular nodular diseases and follicular adenoma, while the other markers were negative. In distinguishing benign and malignant lesions, which constitutes this study, HBME-1, CK19, galectin-3 and TROP-2 were statistically significant (p < 0.001). In distinguishing cases of follicular variant papillary carcinoma from follicular nodular diseases and follicular adenoma, HBME-1 and galectin-3 were statistically significant (p < 0.001). Consequently, in this study, we found that all immunohistochemical markers were effective in distinguishing benign and malignant thyroid lesions. In determining malignancy, HBME-1 had the highest diagnostic accuracy, while CK19 was the most sensitive marker. The sensitivity increased when the markers were used together.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Mürtezaoğlu¹,

Güçer²

2017

pjp

View full text Add to dashboard Cite

show abstract

“…They recommended that a small initial IHC panel including TROP-2 and HBME-1 was accurate for the classification of thyroid follicular patterned lesions with equivocal cytologic features of classic PTC [6]. Bychkov et al [8] examined TROP-2 IHC as a highly accurate marker in the differential diagnosis of PTCs. They showed that nonneoplastic lesions, including nodular goiter, Hashimoto’s thyroiditis, and Grave’s disease, did not show TROP-2 staining.…”

Section: Discussionmentioning

confidence: 99%

“…HBME-1 is a membrane antigen found in the mesothelial cells and in lung, breast, and pancreas adenocarcinomas. TROP-2, also known as tumor-associated calcium signal transducer 2 (TAC-STD2) [6, 8, 11], is a 35-kDa, 323 amino acid, type 1 transmembranous glycoprotein. It is identified in choriocarcinoma and trophoblastic cells.…”

Section: Introductionmentioning

confidence: 99%

“…Its overexpression is seen in the majority of human carcinomas, including colorectal, gastric, and pancreatic adenocarcinoma, squamous cell carcinoma of the oral cavity, non-small cell carcinoma of the lung, and endometrial and ovarian cancers, and rarely in normal tissue. TROP-2 overexpression in carcinoma is related to poor prognosis and aggressive behavior [6, 8, 11], but no single marker is sensitive nor specific for differentiation between benign and malignant thyroid neoplasm. Therefore, in this study, we evaluated the diagnostic utility of a panel consisting of HBME-1 and TROP-2 for differentiation between benign and malignant thyroid lesions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma

Zargari¹,

Mokhtari²

2018

Eur Thyroid J

View full text Add to dashboard Cite

Objective: The diagnosis of thyroid tumors is based on histologic features, but the distinction between benign and malignant thyroid lesions is somehow difficult, especially in lesions with a follicular pattern. Thus, ancillary studies, such as immunohistochemistry (IHC), may be helpful. In this study, we aimed to evaluate the diagnostic value of 2 IHC markers, TROP-2 and HBME-1, in the diagnosis of thyroid cancers. Study Design: A total of 102 cases of thyroid lesions, including papillary thyroid carcinoma (classic variant) (29 cases), follicular variant of papillary thyroid carcinoma (21 cases), multinodular goiter (22 cases), follicular adenoma (24 cases), and follicular carcinoma (6 cases) were selected. The hematoxylin-eosin slides were reviewed for confirmation of diagnosis, and IHC examination for TROP-2 and HBME-1 was performed. Result: HBME-1 had 84% sensitivity and 98% specificity with a positive predictive value (PPV) of 98% and a negative predictive value (NPV) of 83%. TROP-2 had 93% sensitivity and 74% specificity with a PPV of 81% and an NPV of 90% in malignant thyroid lesions. Conclusion: IHC panel consisting of TROP-2 and HBME-1 can be used in equivocal follicular patterned lesions for the diagnosis of thyroid carcinomas.

show abstract

Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors

Liao

Wang

Zeng

et al. 2021

Drug Development Research

View full text Add to dashboard Cite

Trophoblast cell-surface antigen 2 (Trop 2) is a transmembrane glycoprotein that is highly expressed in various cancer types with relatively low or no baseline expression in most normal tissues. Its overexpression is associated with tumor growth and poor prognosis; Trop 2 is, therefore, an ideal therapeutic target for epithelial cancers. Several Trop 2 targeted therapeutics have recently been developed for the treatment of cancers, such as anti-Trop 2 antibodies and antibody-drug conjugates (ADCs), as well as Trop 2-specific cell therapy. In particular, the safety and clinical benefit of Trop 2-based ADCs have been demonstrated in clinical trials across multiple tumor types, including those with limited treatment options, such as triple-negative breast cancer, platinum-resistant urothelial cancer, and heavily pretreated non-small cell lung cancer. In this review, we elaborate on recent advances in Trop 2 targeted modalities and provide an overview of novel insights for future developments in this field.

show abstract

TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma

Cited by 36 publications

References 40 publications

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19

Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma

Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors

Contact Info

Product

Resources

About